Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. A ...

Scholars say the “unknown unknowns” of using artificial intelligence in the workplace may be undermining the technology’s advertised benefits. By Noam Scheiber See more of our coverage in your search ...

The cybercrime operation used AI and distributed phishing kits for campaigns impersonating various trusted brands in texts sent through AT&T, T-Mobile, and Verizon. Outsider Enterprise has been active ...

Just about half of individuals 55 and older said they do not plan on using artificial intelligence, but many of those who have embraced the technology say they’ve had positive personal results. Almost ...

Replimune (REPL) shares climbed more than 60% in the premarket on Friday after the company announced plans to resubmit a marketing application for its lead asset RP1 in the U.S., following its second ...

If you’ve ever turned to artificial intelligence to try to figure out how to handle a tricky situation with a friend or colleague, you’re far from alone. For many, AI has become a modern oracle – a ...

OpenEvidence, an AI-powered medical search tool, has become a fast friend to America’s doctors and is now used by nearly two-thirds of physicians. Your doctor is probably using AI, even if they ...

The website for the popular JDownloader download manager was compromised earlier this week to distribute malicious Windows and Linux installers, with the Windows payload found deploying a Python-based ...

Google is rebranding Circle to Search’s full-screen feature to “Ask about screen,” allowing it to process URLs and PDF data instead of just visible screen content. This update, currently in beta ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

In the fall of 2023, Ilya Sutskever, OpenAI’s chief scientist, sent secret memos to three fellow-members of the organization’s board of directors. For weeks, they’d been having furtive discussions ...